论文部分内容阅读
目的探讨钙剂在腹膜透析患者中的应用指征及药学监护。方法选取26例进行腹膜透析的患者作为研究对象,分析钙剂的应用指征,实施药学监护。结果治疗前,患者的血清钙浓度为(1.96±0.22)mmol/L,钙磷乘积为(2.94±0.71)mmol~2/L~2,甲状旁腺素(iPTH)为(24.81±9.12)pg/ml;治疗3个月后分别为(2.17±0.16)mmol/L、(2.77±0.68)mmol~2/L~2、(21.13±7.56)pg/ml;治疗3个月后血清钙浓度高于治疗前,差异有统计学意义(P<0.05);而钙磷乘积和甲状旁腺素指标与治疗前比较差异无统计学意义(P>0.05)。结论在腹膜透析患者应用钙剂时,要根据患者机体血磷水平和甲状旁腺素指标调整,严密监测,保证钙剂的合理使用,促进患者用药安全。
Objective To explore the application of calcium in patients with peritoneal dialysis indications and medical care. Methods Twenty-six patients undergoing peritoneal dialysis were selected as study subjects, analyzed the indications of calcium application and implemented the pharmacy care. Results Before treatment, the serum calcium concentration was (1.96 ± 0.22) mmol / L, the calcium and phosphorus product was (2.94 ± 0.71) mmol / L and the iPTH was (24.81 ± 9.12) pg / ml, respectively. The levels of serum calcium after 3 months treatment were (2.17 ± 0.16) mmol / L, (2.77 ± 0.68) mmol / L and 21.13 ± 7.56 pg / Before treatment, the difference was statistically significant (P <0.05); while calcium and phosphorus products and parathyroid hormone indicators compared with before treatment was no significant difference (P> 0.05). Conclusion Peritoneal dialysis patients in the application of calcium, according to the patient’s body phosphorus levels and parathyroid hormone adjustment, close monitoring to ensure the rational use of calcium to promote drug safety in patients.